Inhibition of Ephrin B2 Reverse Signaling Abolishes Multiple Myeloma Pathogenesis

By sjmartinez • March 18, 2024

Sasine JP, Kozlova NY, Valicente L, Dukov J, Tran DH, Himburg HA, Kumar S, Khorsandi S, Chan A, Grohe S, Li M, Kan J, Sehl ME, Schiller GJ, Reinhardt B, Singh BK, Ho R, Yue P, Pasquale EB, Chute JP. Inhibition of Ephrin B2 Reverse Signaling Abolishes Multiple Myeloma Pathogenesis. Cancer Res. 2024 Mar 15;84(6):919-934. doi: 10.1158/0008-5472.CAN-23-1950. PMID: 38231476; PMCID: PMC10940855.

Tags: Hematology/Oncology, Publications

Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity that Associates with a Clinically Aggressive Subtype of Prostate Cancer

Zhang L, Teng PC, Cavassani KA, Wang J, Grasso C, Watson J, Chen Z, Tu KH, Salumbides B, Rohena-Rivera K, Gevorkian L, Kim M, You[...]

Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study

McCann KE, Osman N, Cannon J, Brent L, Wang Y, Tepsick J, Mandora PV, Miller V, Martin N, Kaklamani VG. Goserelin 3-month depot shows non-inferiority[...]

A plain language summary of quality of life with sacituzumab govitecan treatment in the TROPiCS-02 study in participants with breast cancer (HR-positive/HER2-negative)

Rugo HS, Schmid P, Tolaney SM, Marmé F, Bardia A, Spears PA, Cortés J. A plain language summary of quality of life with sacituzumab govitecan[...]